iBio (IBIO) Registration Filing summary

Company overview and business model

• Operates as a preclinical stage biotechnology company focused on AI-driven precision antibody development for cardiometabolic and obesity indications.

• Utilizes an AI Drug Discovery Platform to identify novel biologics targeting unmet needs in obesity, aiming for targeted fat loss and muscle preservation.

• Pipeline includes multiple preclinical candidates, with IBIO-600 expected to enter Phase 1a trials in 1H 2026 and IBIO-610 in early 2027.

• Pursues strategic collaborations and out-licensing to expand platform use beyond core areas, including immunology and vaccines.

Financial performance and metrics

• Net tangible book value as of December 31, 2025, was $1.74 per share, increasing to $2.37 per share post-offering (assuming full $100M raise at $2.47/share).

• Pro forma net tangible book value after recent warrant exercises and private placements was $2.34 per share.

• Immediate dilution to new investors is estimated at $0.10 per share at the assumed offering price.

Use of proceeds and capital allocation

• Net proceeds are intended for working capital and general corporate purposes, including potential acquisitions, licensing, investments in assets, technologies, product candidates, or intellectual property, and repurchasing securities.

• Management retains broad discretion over allocation and may adjust plans based on operational needs and market conditions.